Publications

2024

• S. Colak, S. Di Donato, L. A. Bissell, T. Barnes, C. P. Denton, M. Nisar, V. Kakkar, F. Del Galdo Content Validity and Sensitivity to Change of ScleroID Through the Natural History of Scleroderma. a Validated Tool to Measure the Impact of SSc on How Patients Feel and Function. American College of Rheumatology Convergence 2024
• Aromatase inhibitors and fracture prevention - do 2017 guidelines work in real world? Mirza A, Naing ZW, Khonsari P, Khan H, Abbas AK, Nisar MK. BJC Rep. 2024 May 1;2(1):36. doi: 10.1038/s44276-024-00059-5.
• MSK playbook: Hand osteoarthritis. Dr Mohammed Subhi, Mr Ian Gatt, Dr Irfan Ahmed, Dr Imran Lasker, Dr Rifat Hassan, Mr Jack March, Mr Ryan Linn, Dr Muhammad Nisar
• Do real-world treatment patterns reflect PsA recommendations? Results from the PRO-SPIRIT study. William Tillett, Muhammad Nisar, Vinod Chandran, Khai Jing Ng, Marcus Ngantcha, Cedric Laedermann, Sebastian Moyano, Rieke Alten, Lars Erik Kristensen, Dennis McGonagle DGRh (2024) Deutsche Gesellschaft fur Rheumatologie - 52 Kongress
• Do real-world treatment patterns reflect PsA recommendations? Results from the PRO-SPIRIT study. William Tillett, Muhammad Nisar, Vinod Chandran, Khai Jing Ng, Marcus Ngantcha, Cedric Laedermann, Sebastian Moyano, Rieke Alten, Lars Erik Kristensen, Dennis McGonagle Società Italiana di Reumatologia (SIR) 2024: 27-30 November 2024, Rimini
• Do real-world treatment patterns reflect PsA recommendations? Results from the PRO-SPIRIT study. William Tillett, Muhammad Nisar, Vinod Chandran, Khai Jing Ng, Marcus Ngantcha, Cedric Laedermann, Sebastian Moyano, Rieke Alten, Lars Erik Kristensen, Dennis McGonagleEULAR 2024
• Do real-world treatment patterns reflect PsA recommendations? Results from the PRO-SPIRIT study. William Tillett, Muhammad Nisar, Vinod Chandran, Khai Jing Ng, Marcus Ngantcha, Cedric Laedermann, Sebastian Moyano, Rieke Alten, Lars Erik Kristensen, Dennis McGonagle Societe Francaise de Rhumatologie (SFR 2024) - 37th Annual French Congress of Rheumatology, Paris, 8-10th December 2024
• The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope. Hannah J, Rodziewicz M, Mehta P, Heenan KM, Ball E, Barratt S, Carty S, Conway R, Cotton CV, Cox S, Crawshaw A, Dawson J, Desai S, Fahim A, Fielding C, Garton M, George P, Gunawardena H, Kelly C, Khan F, Koduri G, Morris H, Naqvi M, Perry E, Riddell C, Sieiro Santos C, Spencer LG, Chaudhuri N, Nisar MK. Rheumatol Adv Pract. 2024 Apr 18;8(2):rkae056. doi: 10.1093/rap/rkae056. eCollection 2024.
• Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, D'Agostino MA, McInnes IB, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga T, Toes R, Georgiou E, Kelly J, Murphy C, Prevost AT; APIPPRA study investigators. Lancet. 2024 Mar 2;403(10429):838-849. doi: 10.1016/S0140-6736(23)02649-1. Epub 2024 Feb 13.
• Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets. De Lorenzis E, Kakkar V, Di Donato S, Wilson M, Barnes T, Denton C, Derrett-Smith E, Douglas K, Helliwell P, Herrick AL, Saleem B, Nisar M, Morley C, Green L, Alcacer-Pitarch B, Del Galdo F. RMD Open. 2024 Jan 12;10(1):e003216. doi: 10.1136/rmdopen-2023-003216.
• The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope. Hannah J, Rodziewicz M, Mehta P, Heenan KM, Ball E, Barratt S, Carty S, Conway R, Cotton CV, Cox S, Crawshaw A, Dawson J, Desai S, Fahim A, Fielding C, Garton M, George P, Gunawardena H, Kelly C, Khan F, Koduri G, Morris H, Naqvi M, Perry E, Riddell C, Sieiro Santos C, Spencer LG, Chaudhuri N, Nisar MK. Rheumatol Adv Pract. 2024 Apr 18;8(2):rkae056. doi: 10.1093/rap/rkae056. eCollection 2024.
• Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet Child Adolesc Health. 2024 Mar;8(3):190-200. doi: 10.1016/S2352-4642(23)00316-4. Epub 2024 Jan 22.
• Real world clinical outcomes of patients with moderate-to-severe rheumatoid arthritis initiating upadacitinib in the United Kingdom: Interim analysis from a prospective observational cohort study (ENDEAVOUR) James Taylor, Srinivasan Srirangan, Marwan Bukhari, Syed Bilgrami, Muhammad K Nisar, Stephen McDonald, Nicola Goodson, Andrew Allard, Alison Kinder, Michael Green et al. Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.148
• EULAR Scleroid as comprehensive patient reported outcome in systemic sclerosis: Longitudinal validation of content validity and sensitivity to change S. Colak, S. Di Donato, L. A. Bissell, T. Barnes, C. P. Denton, M. Nisar, V. Kakkar, F. Del Galdo Ann Rheum Dis volume 83, supplement 1, year 2024, page 1063
• ‘Do real-world treatment patterns reflect PsA recommendations? Results from the PRO-SPIRIT study’. 7th World Psoriasis & Psoriatic arthritis conference 2024

2023

• Should All Patients Trial Subcutaneous Methotrexate Prior to Commencing Biologic Therapy? A Real World Study. Mirza A, Nisar MK. Mediterr J Rheumatol. 2023 Sep 4;35(1):115-122. doi: 10.31138/mjr.140423.sat
• Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial. Hall FC, Cheriyan J, Cope AP, Galloway J, Wilkinson I, Bond S, Norton S, Banham-Hall E, Bayes H, Kostapanos M, Nodale M, Petchey WG, Sheeran T, Underwood J, Jayne DR; TACTIC-R Investigators Group. Lancet Respir Med. 2023 Nov 14:S2213-2600(23)00376-4. doi: 10.1016/S2213-2600(23)00376-4. Online ahead of print. PMID: 37977159
• Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet Diabetes Endocrinol. 2023 Dec;11(12):905-914. doi: 10.1016/S2213-8587(23)00253-X. Epub 2023 Oct 18. PMID: 37865101
• Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Electronic address: [email protected]; RECOVERY Collaborative Group. Lancet. 2023 May 6;401(10387):1499-1507. doi: 10.1016/S0140-6736(23)00510-X. Epub 2023 Apr 13. PMID: 37060915 Free PMC article. Clinical Trial.
• Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease. Taylor PC, Askari A, Choy E, Ehrenstein MR, Else S, Nisar MK.BMC Med. 2023 Feb 14;21(1):55. doi: 10.1186/s12916-023-02746-5.
• Clinical Trajectories of multifactorial hand function deterioration in systemic sclerosis (EULAR 2023)
• IL-17 or TNF inhibitors - real world impact of shared decision making in a nurse led biologics service (EULAR 2023)
• You First: a cost-effective nurse-led patient support program - retrospective analysis from a large multi-ethnic setting ORAL PRESENTATION (EULAR 2023)

2022

• Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. RECOVERY Collaborative Group. Lancet. 2022 Jul 30;400(10349):359-368. doi: 10.1016/S0140-6736(22)01109-6. PMID: 35908569 Free PMC article.
• Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5. PMID: 35151397 Free PMC article. Clinical Trial.
• Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet. 2022 Jan 8;399(10320):143-151. doi: 10.1016/S0140-6736(21)01825-0. Epub 2021 Nov 17. PMID: 34800427 Free PMC article. Clinical Trial.
• Jawad II, Nisar MK. How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study. Eur J Rheumatol. 2022 Apr;9(2):100-103.
• Aromatase inhibitors and fracture prevention – do new guidelines work in real world? ORAL PRESENTATION (EULAR 2022)
• Aromatase inhibitors and skeletal health – natural history and interventional epidemiology (EULAR 2022)
• Drive-through phlebotomy – does it work for cDMARDs monitoring? (EULAR 2022)
• Serum interferon score predicts severity of patient reported hand disability in systemic sclerosis (EULAR 2022)
• Drive-through phleobotomy – is this the future? (BSR 2022)
• Aromatase inhibitors and fracture prevention- is our current approach correct? (ESMO)
• Which admission parameters are associated with poor COVID -19 outcome? A real world study (Critical care symposium 2022)
• Aromatase inhibitors and skeletal health – do new guidelines prevent fractures? (WCO-IOF-ESCEO 2022)
• Aromatase inhibitors and skeletal health – natural history and interventional epidemiology (WCO-IOF-ESCEO 2022)

2021

• Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Džavík V, Effron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Froess JD, Fu Z, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Knudson MM, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Gallego Lima F, Linstrum K, Litton E, Lopez-Sendon J, Lother SA, Marten N, Saud Marinez A, Martinez M, Mateos Garcia E, Mavromichalis S, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nicolau JC, Nunez-Garcia B, Park JJ, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Pompilio M, Quigley JG, Rosenson RS, Rost NS, Rowan K, Santos FO, Santos M, Santos MO, Satterwhite L, Saunders CT, Schreiber J, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Singhal AB, Slutsky AS, Solvason D, Stanworth SJ, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Widmer RJ, Wilson JG, Yuriditsky E, Zhong Y, Berry SM, McArthur CJ, Neal MD, Hochman JS, Webb SA, Zarychanski R. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4. PMID: 34351722 Free PMC article. Clinical Trial.
• Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR, Turgeon AF, Escobedo J, Huang DT, Bradbury CA, Houston BL, Kornblith LZ, Kumar A, Kahn SR, Cushman M, McQuilten Z, Slutsky AS, Kim KS, Gordon AC, Kirwan BA, Brooks MM, Higgins AM, Lewis RJ, Lorenzi E, Berry SM, Berry LR, Aday AW, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Costantini TW, de Brouwer S, Derde LPG, Detry MA, Duggal A, Džavík V, Effron MB, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Galanaud JP, Galen BT, Gandotra S, García-Madrona S, Girard TD, Godoy LC, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Hamburg NM, Haniffa R, Hanna G, Hanna N, Hegde SM, Hendrickson CM, Hite RD, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Hudock K, Hunt BJ, Husain M, Hyzy RC, Iyer VN, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski AL, King AJ, Knudson MM, Kornblith AE, Krishnan V, Kutcher ME, Laffan MA, Lamontagne F, Le Gal G, Leeper CM, Leifer ES, Lim G, Lima FG, Linstrum K, Litton E, Lopez-Sendon J, Lopez-Sendon Moreno JL, Lother SA, Malhotra S, Marcos M, Saud Marinez A, Marshall JC, Marten N, Matthay MA, McAuley DF, McDonald EG, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Moore SC, Morillo Guerrero R, Mouncey PR, Murthy S, Nair GB, Nair R, Nichol AD, Nunez-Garcia B, Pandey A, Park PK, Parke RL, Parker JC, Parnia S, Paul JD, Pérez González YS, Pompilio M, Prekker ME, Quigley JG, Rost NS, Rowan K, Santos FO, Santos M, Olombrada Santos M, Satterwhite L, Saunders CT, Schutgens REG, Seymour CW, Siegal DM, Silva DG Jr, Shankar-Hari M, Sheehan JP, Singhal AB, Solvason D, Stanworth SJ, Tritschler T, Turner AM, van Bentum-Puijk W, van de Veerdonk FL, van Diepen S, Vazquez-Grande G, Wahid L, Wareham V, Wells BJ, Widmer RJ, Wilson JG, Yuriditsky E, Zampieri FG, Angus DC, McArthur CJ, Webb SA, Farkouh ME, Hochman JS, Zarychanski R. N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4. PMID: 34351721 Free PMC article. Clinical Trial.
• Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, Annane D, Swaidan LA, Beane A, Beasley R, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Buzgau A, Cheng A, De Jong M, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Fowler R, Girard TD, Goligher EC, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Huang DT, King AJ, Lamontagne F, Lawler PR, Lewis R, Linstrum K, Litton E, Lorenzi E, Malakouti S, McAuley DF, McGlothlin A, Mcguinness S, McVerry BJ, Montgomery SK, Morpeth SC, Mouncey PR, Orr K, Parke R, Parker JC, Patanwala AE, Rowan KM, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tong SYC, Turgeon AF, Turner AM, Van de Veerdonk FL, Zarychanski R, Green C, Berry S, Marshall JC, McArthur C, Angus DC, Webb SA; REMAP-CAP Investigators. Intensive Care Med. 2021 Aug;47(8):867-886. doi: 10.1007/s00134-021-06448-5. Epub 2021 Jul 12. PMID: 34251506 Free PMC article. Clinical Trial. 10
• Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14. PMID: 34000257 Free PMC article. Clinical Trial.
• Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. PMID: 33933206 Free PMC article. Clinical Trial.
• Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25. PMID: 33631065 Free PMC article. Clinical Trial.
• Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. RECOVERY Collaborative Group. Lancet. 2021 Feb 13;397(10274):605-612. doi: 10.1016/S0140-6736(21)00149-5. Epub 2021 Feb 2. PMID: 33545096 Free PMC article. Clinical Trial.
• Dexamethasone in Hospitalized Patients with Covid-19. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17. PMID: 32678530 Free PMC article. Clinical Trial.
• Biomarkers Predict In-Hospital Major Adverse Cardiac Events in COVID-19 Patients: A Multicenter International Study. J. Clin. Med. 2021; 10(24): 5863
• Can a specialist nurse lead a comprehensive osteoporosis service with remote supervision – an innovative concept (EULAR 2021)
• Can rheumatic conditions associated interstitial lung diseases be managed in a district general hospital – results from a longitudinal outcomes survey (EULAR 2021)
• Normocalcaemic hyperparathyroidism and bone health – worse than anticipated? (EULAR 2021)
• Nurse led remote management of osteoporosis – do patients approve? (EULAR 2021)
• Should all patients trial subcutaneous methotrexate prior to commencing biologic therapy – a real world study (EULAR 2021)

2020

• The Differential Effect of Antibodies on Radiographic Progression in Rheumatoid Arthritis. Minocha A, Kukran S, Yee P, Nisar M. Mediterr J Rheumatol. 2020 Dec 22;31(4):393-399. doi: 10.31138/mjr.31.4.393. eCollection 2020 Dec. PMID: 33521571 Free PMC article.
• Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. RECOVERY Collaborative Group; Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson JA, White NJ, Juszczak E, Haynes R, Landray MJ. N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8. PMID: 33031652 Free PMC article. Clinical Trial.
• Rauf M, Sen S, Levene A, Nisar MK. Giant cell hepatitis - a rare association with connective tissue disease. Mediterr J Rheumatol. 2020 Mar 31;30(4):224-227
• How well are biologics retained in psoriatic arthritis - a real world study (EULAR 2020)
• Impact of tolerability on retention of cDMARDs in psoriatic arthritis - is it a concern? (EULAR 2020)
• Should a combined rheumatology-pulmonology interstitial lung disease service be confined to tertiary centres - a service evaluation (EULAR 2020)
• Optical coherence tomography for hydroxychloroquine eye monitoring - should we worry? (EULAR 2020)
• Teriparatide switch to biosimilar - is it cost effective? (EULAR 2020)
• Do antibodies have differential effect on radiographic progression in RA? (EULAR 2020)
• Switch to biosimilar adalimumab - is it cost effective? (EULAR 2020)
• Can dedicated community health hubs improve physical activity in a multi-ethnic rheumatology practice? (EULAR 2020)
• Can a specialist nurse replace a consultant - an innovative model for osteoporosis care (EULAR 2020)
• Which antibody is more important for radiographic erosions in RA? (BSR 2020)
• How well are conventional DMARDs tolerated in psoriatic arthritis - a real world study (BSR 2020)
• Can we manage osteoporosis without patients ever seeing a consultant? (BSR 2020)
• Teriparatide use in real world - can we expect cost savings with a switch to generic version? (BSR 2020)
• Biologic retention in psoriatic arthritis - a real world study (BSR 2020)
• Switching to biosimilar adalimumab: a real world study (BSR 2020)

2019

• A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM; TRACE RA Consortium. Arthritis Rheumatol. 2019 Sep;71(9):1437-1449. doi: 10.1002/art.40892. Epub 2019 Jul 22. PMID: 30983166 Free PMC article. Clinical Trial.
• Mothojakan NB, Gore J, Nisar MK. Does Biologic Survival Depend on Co-Prescribed Methotrexate Dose in Established Rheumatoid Arthritis? A Real-World Study. Eur J Rheumatol. 2019; 25;7(1):21-25
• Nisar MK. Combining Secukinumab and Fingolimod to Successfully Treat Ankylosing Spondylitis and Multiple Sclerosis - A Novel Approach. Biologicals. 2019 Jul;60:93-94.
• Nisar MK. Early arthritis clinic is cost effective, improves outcomes and reduces biologic use Clin Rheumatol. 2019 Jun;38(6):1555-1560
• Nisar MK. Early arthritis clinic is effective for rheumatoid and psoriatic arthritides Rheumatol Int. 2019 Apr;39(4):657-662
• Nisar MK. Combining Secukinumab and Apremilast to Successfully Treat Refractory Psoriatic Skin and Joint Disease: A Novel Approach. Eur J Rheumatol 2019 Jan;6(1):60-61
• Nisar MK. Crystallising the Role of Adrenocorticotrophic Hormone in the Management of Acute Gout: A Review. Clin Exp Rheumatol Jan-Feb 2019;37(1):137-145
• Etanercept biosimilar switch: can it be successful without clinic review? (EULAR 2019)
• Osteoporosis in primary care – are we missing a trick (EULAR 2019)
• Rituximab biosimilar non-medical switch – does it work? (EULAR 2019)
• Are psoriatic arthritis outcomes better in an early arthritis service? Study from a national award winning centre (EULAR 2019)
• Does biologic retention vary with methotrexate co-prescription dose in established RA? A real world study (BSR 2019)
• Rituximab biosimilar and miliary tuberculosis: vigilance is the key (BSR 2019)
• Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis: a novel approach (BSR 2019)
• Secukinumab and solid organ cancer: are they mutually exclusive? (BSR 2019)
• Does the quality & outcomes framework (QOF) indicator for osteoporosis work? A primary care study (BSR 2019)
• Do dedicated early arthritis clinics improve psoriatic arthritis outcomes? A real world study (BSR 2019)
• Switching to biosimilar rituximab: a real world study (BSR 2019)
• Nisar MK. Early arthritis service is cost-effective, improves outcomes and reduces biologic use Clin Med March 2019 19:78; doi:10.7861/clinmedicine.19-2-s78

2018

• Nisar MK, Mirza W, Rafiq A, Eisenhut M. Adherence to biological therapy – does it vary with ethnicity? Biologicals 2018;54:28-32
• Begum J, Nisar MK. Rheumatology nurse specialists and corticosteroids prescription-Is it safe? Int J Nurs Stud. 2018 Mar;79:84-85.
• DMARD monitoring guidelines and shared prescribing in primary care – is more education required? (EULAR 2018)
• Rheumatology nurse specialists and corticosteroid prescribing – does it conform to EULAR guidelines? (EULAR 2018)
• Can community pharmacy services be the missing link in achieving early diagnosis of psoriatic arthritis? (EULAR 2018)
• Is dose banding of infliximab cost effective – results from real world implementation (EULAR 2018)
• Early arthritis service is cost effective, improves outcomes and reduces biologic use (EULAR 2018)
• ACTH reborn – modernising the evidence (BSR 2018)
• Early Arthritis Service is Cost Effective, Improves Outcomes and Reduces Biologic Use (BSR 2018)
• Combining Secukinumab and Apremilast to Successfully Treat Refractory Psoriatic Skin and Joint Disease: A Novel Approach (BSR 2018)
• Can Community Pharmacy Services be the Missing Link in Achieving Early Diagnosis of Psoriatic Arthritis? (BSR 2018)
• Is the Dose Banding of Infliximab Cost Effective? A Real World Analysis (BSR 2018)
• Do Dedicated Early Arthritis Clinics Improve Patient Outcomes? A Real World Study (BSR 2018)
• Switching to biosimilar Rituximab – a real world study (BSR 2018)
• Mycophenolate Mofetil – Treating an Elusive Multi System Disease (BSR 2018)
• Rheumatology nurse specialists and corticosteroid prescription – is it safe? (BSR 2018)
• BSR DMARD Guidelines and Shared Prescribing in Primary Care: Is it reliable? (BSR 2018)

2017

• Begum J, Nisar MK. Training rheumatology nurse specialists: Are we doing the job right? Eur J Rheumatol. 2017 Sep;4(3):234-235.
• Nisar MK, Packianathan C. Chikungunya and bilateral sacroiliitis-is there a link?. Eur J Rheumatol. 2017 Mar;4(1):81-82.
• Begum J, Nisar MK. Rheumatology nurse specialists and DMARD education - Is it fit for purpose? Int J Nurs Stud. 2017 Apr;69:98-99.
• Do junior doctors prescribe DMARDs safely? (EULAR 2017)
• Rheumatology nurse specialists and DMARD prescription – where are we now? (EULAR 2017)
• Training Rheumatology nurse specialists – what does the future hold? (EULAR 2017)
• Headache – not always fibromyalgia (BSR 2017)
• Chikungunya and spondyloarthropathy – is there an association (BSR 2017)
• Training rheumatology nurse specialists – where are we now? (BSR 2017)
• Rheumatology nurse specialists and DMARD education – is it fit for purpose? (BSR 2017)
• Adherence to subcutaneous biologic therapies – does it vary with ethnicity? (BSR 2017)
• DMARD prescription and junior doctors – is it safe? (BSR 2017)
• Nisar MK. Modern management of gout-crystallising the evidence [AGM 2017]
• Rheumatology wins national award Sep 2017 (L&D Community/GP newsletter)
• Recognition of Rheumatology department in the national audit Mar 2017 (L&D Community/GP newsletter)
• Rheumatology specialist nurse goes international (L&D Community/GP newsletter)
• Rheumatology department tops national audit Feb 2017 (Ambassador magazine L&D)
• Recognition of Rheumatology department in the national audit Jan 2017 (L&D Community/GP newsletter)

2016

• Musculoskeletal examination in patients presenting with falls and junior doctors training: still a concern. Osteoporosis Int 2016;27(suppl 1):192 (World Congress on Osteoarthritis, Osteoporosis and musculoskeletal conditions 2016)
• Rheumatology department transforming Mar 2016 (L&D Community/GP newsletter)
• Impact of psoriasis – deeper than you think Jun 2016 (L&D Community/GP newsletter- with Dr T Baqai as lead author)
• Rheumatology service expansion Aug 2016 (L&D Community/GP newsletter)
• Boost for Rheumatology Service at the L&D Aug 2016 (Ambassador magazine L&D)
• Recognition of Rheumatology department in National Early Arthritis audit Nov 2016 (British Society of Rheumatology website)

2015

• Nisar MK, Rafiq A, Östör AJK. Biologic therapy for inflammatory arthritis and latent tuberculosis:real world experience from a high prevalence area in the UK. Clin Rheumatol. 2015;34:2141-5
• Nisar MK. Cupping (Hijama) treatment: Benign or sinister? J Patient Saf 2015 Mar 16
• Nisar MK, Rafiq A, Ostor AJK. Tuberculosis and Biologics: Real World experience from High tuberculosis prevalence area in the UK. Ann Rheum Dis2015;74(Suppl2): 788
• Nisar MK, Rafiq A, Ostor AJK. Tuberculosis and Biologics: Real World experience from High tuberculosis prevalence area. Rheumatology 2015;51(suppl1):i91 [BSR 2015]
• Nisar MK, Packianathan CI. Chikungunya and bilateral sacroiliitis – is there a link? AnnRheum Dis 2015;74(suppl 2):1213

2014

• Oomatia A, Ramabhadran B, Fishman D, Nisar MK. Musculoskeletal examination and junior doctors: still cause for concern? Rheumatology 2014;53(suppl1):i156 [BSR 2014]

2013

• Nisar MK, Östör AJK. Pulmonary Complications of Biological Therapies in Children with Rheumatic Diseases. Paediatr Respir Rev. 2013 Dec;14(4):236-41
• Nisar MK, Östör AJK. TNF antagonists and Shingles: Is Vaccination Advisable? Ann Rheum Dis. 2013 May;72(5):e1
• Nisar MK, Masood F, Cookson P, Sansome A, Östör AJK. What do we know about juvenile idiopathic arthritis and vitamin D? A systematic literature review and meta-analysis of current evidence. Clin Rheumatol. 2013 Jun;32(6):729-34
• Brode S, Nisar MK, Östör AJK. Same day or historical ESR for disease activity score measurement, does it matter? Clinical Rheumatol. 2013 Feb;32(2):261-5
• Nisar MK. Choosing appropriate biologic therapy [BSR 2013]
• Nisar MK, Kuttikat AV, Ramabhadran B, Fishman D. Lemmierre’s Syndrome- a rare cause of septic polyarthritis. Rheumatol Int. 2013 Mar;33(3):817-8
• Nisar MK et al. Is there a link between Vitamin D and juvenile idiopathic arthritis? Ann Rheum Dis [EULAR 2013]
• Nisar MK et al. What do we know about juvenile idiopathic arthritis and vitamin D? A systematic literature review and meta-analysis of current evidence. Ann Rheum Dis [EULAR 2013]
• Hall FC, Malaviya AP, Nisar MK et al. A comparison of near-infrared spectroscopy and laser doppler flowmetry as tools for assessing severity of hand ischaemia in systemic sclerosis. Rheumatology 2013;52(suppl1):i157

2012

• Nisar MK, Östör AJK. The role of tocilizumab monotherapy in the treatment of rheumatoid arthritis. Int J Clinical Rheumatol. 2012 Feb;7(1):9-19
• Nisar MK, Östör AJK. Comment on: Non-infectious pulmonary toxicity of rituximab: a systematic review: reply. Rheumatology. 2012 Sep 6 [doi:10.1093/rheumatology/kes205]
• Zhang N, Wilkinson S, Riaz M, Östör AJK, Nisar MK. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? a systematic literature review. Clin Exp Rheumatol. 2012 Nov-Dec;30(6):962-71
• Kim S, Östör AJK, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int. 2012 Sep;32(9):2601-4
• Nisar MK, El-Essawy B, Kuttikat AV, Ramabhadran B, Fishman D. Musculoskeletal examination and junior doctors- cause for concern? Int J Rheum Dis. 2012 Jun;15(3):e43-4
• Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Östör AJK. Non-infectious pulmonary toxicity of Rituximab: a systematic review. Rheumatology. 2012 Apr;51(4):653-62
• Zhang N, Wilkinson S, Riaz M, Östör AJK, Nisar MK. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? a systematic literature review. Rheumatology 2012;51(suppl3):iii114 [BSR 2012]
• Malaviya AP, Hadjinicolaou AV, Nisar MK et al. The hand ischaemia score: a novel hand ischaemia outcome measure in systemic sclerosis. Rheumatology 2012;51(suppl3):iii83 [BSR 2012] 3rd prize at Deanery’s poster exhibition
• Hadjinicolaou AV, Malaviya AP, Nisar MK et al. Regional oxygen saturation as a novel outcome measure in systemic sclerosis-associated hand ischaemia. Rheumatology 2012;51(suppl3):iii83 [BSR 2012]

2011

• Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Östör AJK. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases- a systematic literature review. Rheumatology. 2011 Dec;50(12):2297-305 & Rheumatology Middle East Vol 4 Issue 1
• Nisar MK, Östör AJK. The role of Tumour Necrosis Factor-α in the treatment of rheumatoid arthritis- a review. European Musculoskeletal rev. 2011;6(3):174–8
• Nisar MK, Mya T. Spontaneous coronary artery dissection (SCAD) in the context of positive anticardiolipin antibodies and clinically undiagnosed systemic lupus erythematosus (SLE). Lupus 2011 Nov;20(13):1436-8
• Nisar MK, Baburaj K. A challenging case of gout and failure of anti-TNF therapy: are current treatments adequate? Int J Rheum Dis. 2011 Aug;14(3):e42-3
• Gout T, Östör AJK, Nisar MK. Lower gastro-intestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol. 2011 Nov;30(11):1471-4
• Brode S, Nisar MK, Östör AJK. Same day or historical ESR for disease activity score-28 measurement, does it matter? Ann Rheum Dis 2011;70(suppl3):587
• Brode S, Nisar MK, Östör AJK. Do we need same day ESR for DAS-28 measurement? Rheumatology 2011;50(suppl3):iii93-iii104 (abstract no 142)
• Nisar MK, Kuttikat AV, Ramabhadran B. An audit of musculoskeletal (MSK) examination in medical patients presenting with falls and a survey of junior doctors’ locomotor examination skills. Ann Rheum Dis 2011;70(suppl3):112
• Gout T, Nisar MK, Östör AJK. A systematic literature review of lower gastro-intestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab. Ann Rheum Dis 2011;70(suppl3):722
• Hadjinicolaou AV, Nisar MK, Östör AJK. Non-infectious pulmonary toxicity of rituximab- a systematic literature review. Ann Rheum Dis 2011;70(suppl3):722

2010

• Nisar MK, Östör AJK. Disease remission the goal of therapy in rheumatoid arthritis. Practitioner.2010;254:17-21
• Nisar MK, Östör AJK. Educational and psychological issues around osteoarthritis.2010. Doctors.net.uk module
• Ramabhadran B, Fishman D, Nisar MK, Kuttikat AV. Lemmiere’s Syndrome- a rare cause of septic polyarthritis. Ann Rheum Dis 2010;69(suppl3):706

Lectures

2024

• Jan 2024 ‘2023 Rheumatology updates’ Regional rheumatology nurse forum Newmarket UK
• Jan 2024 ‘Research strategy for Bedfordshire’ Beds regional research forum Luton UK
• Feb 2024 ‘Latest in osteoporosis’ Beds GP forum, Bedford UK
• Feb 2024 ‘Psoriatic arthritis and chronic pain management’ West Midlands Rheumatology meeting Worcester UK
• Feb 2024 ‘Management of hot joint’ East Midlands SrR forum, Northampton UK
• Mar 2024 ‘How to differentiate inflammatory arthritis’ Herts GP symposium, Welwyn Garden City UK
• Mar 2024 ‘ACR updates’ National rheumatology nurse meeting, Birmingham UK
• Mar 2024 ‘Metabolic bone conundrums for national FRCS Orthopaedics course, Luton UK
• Mar 2024 ‘Latest updates in spondyloarthropathy’ Regional rheumatology forum, Derby UK
• Mar 2024 ‘Updates in JAK1 inhibition’ Regional rheumatology nurse forum, Derby UK
• Mar 2024 ‘You First program’ Midlands Rheumatology meeting, Birmingham UK
• Apr 2024 ‘Management of Spondyloarthropathy and associated pain’ East Midlands Rheumatology forum Northampton UK
• Apr 2024 ‘Role of anti IL17 therapy in Spondyloarthropathy management’ Wales rheumatology meeting Swansea UK
• Apr 2024 ‘Scope of Systemic autoimmune rheumatic diseases associated interstitial lung diseases national guidelines’ British society of Rheumatology annual meeting Liverpool UK
• May 2024 ‘Role of JAK inhibitors in light of EMA update’ National meeting London UK
• May 2024 ‘IL17 inhibition in SpA’ Regional rheumatology meeting Hereford UK
• Jun 2024 ‘Complex SpA case management’ South East regional meeting Isle of Wight UK
• Jun 2024 ‘How to choose a JAK inhibitor’ Regional Rheumatology specialist practitioners meeting Hitchin UK
• Jul 2024 ‘Women’s health in rheumatology’ East of England rheumatology specialist nurse meeting Newmarket UK
• Jul 2024 ‘Role of nurse in metabolic bone care’ Clinical audit and effectiveness committee meeting Luton UK
• Jul 2024 ‘Inflammatory arthritis and the role of MDT’ SriLankan doctors national Alumni meeting London UK
• Aug 2024 ‘How to write a business case’ East of England rheumatology specialist trainees meeting Newmarket UK
• Sep 2024 ‘JAK 1 inhibition and RA’ Regional Rheumatology meeting Hillingdon UK
• Oct 2024 ‘Optimising Methotrexate’ National nurse forum Luton UK
• Oct 2024 ‘Management of common rheumatic diseases’ Qatar’s GP forum London UK
• Oct 2024 ‘Basic imaging for nurse specialists’ British Society of Rheumatology core skills course for nurses Cambridge UK
• Oct 2024 ‘Methotrexate – its history and applications’ national specialist nurse meeting London UK
• Oct 2024 ‘Management of Spondyloarthropathy’ All Wales rheumatology forum Cardiff UK
• Nov 2024 ‘Future for Sjogren disease research’ national research strategy meeting London UK
• Nov 2024 ‘Moderate RA service’ All Wales Rheumatology forum Cardiff UK
• Nov 2024 ‘Real world experience of Secukinumab flexible dosing in psoriatic arthritis’ Regional rheumatology meeting Ayr Scotland UK
• Nov 2024 ‘Steroids – friend or foe’ Evolution in rheumatology national meeting London UK
• Nov 2024 ‘Moderate RA’ regional rheumatology meeting Rotherham UK
• Nov 2024 ‘Selecting data to inform management of RA’ rheumatology meeting Cheltenham UK

2023

• Jan 2023 'JAK1 inhibition in inflammatory arthritis' Hampshire Rheumatology meeting UK
• Jan 2023 'JAK1 inhibitors' Pan Wales Rheumatology meeting Cardiff UK
• Feb 2023 'Opportunities and challenges in implementing new services' National Pharmaceutical forum London UK
• Feb 2023 'Oral molecules in the management of inflammatory arthritis' East Kent Rheumatology forum UK
• Feb 2023 'How to select appropriate therapy - role of nurse specialists' national nurse meeting London UK
• Feb 2023 'Role of GPs in diagnosis early inflammatory arthritis' Bedfordshire GPs forum UK
• Mar 2023 'Treating moderate RA - to escalate or not to escalate? That is the question' National rheumatology nurse meeting Birmingham UK
• Mar 2023 'Safety update - ORAL surveillance and EMA safety alert - what does this mean for rheumatology nurses?' National rheumatology nurse meeting UK
• Mar 2023 'The assessment and burden of psoriatic arthritis with secukinumab case studies' Wales rheumatology registrars meeting UK
• Mar 2023 'Transferring knowledge into clinical practice: A rheumatologist's perspective' National gastroenterology meeting London UK
• Apr 2023 'Oral agents in spondyloarthritis' All Wales rheumatology meeting Cardiff UK
• Apr 2023 'Upadacitinib in clinical practice' North West rheumatology Forum Blackpool UK
• Apr 2023 'JAK1 inhibition in real world' National rheumatology fringe meeting Manchester UK
• Apr 2023 'CRP normal variant of RA' National rheumatology meeting Manchester UK
• Apr 2023 'JAK1 inhibitors and best practice' North East rheumatology meeting Morecambe bay UK
• Apr 2023 'Doctor and rheumatology nurse - a proven team: The English model for Germany?' German Rheumatology congress Berlin Germany
• May 2023 'Upadacitinib in spondyloarthritis' Departmental rheumatology meeting Hull UK
• May 2023 Chaired 'Real world safety of Baricitinib' National rheumatology meeting Luton UK
• May 2023 'Real world data of JAK1 inhibitors' Rheumatology meeting Hereford UK
• May 2023 'Hitchhikers guide to a different galaxy - learnings from USA and the Netherlands' Grand round Luton UK
• Jun 2023 'Regulatory process for drug introduction' Milan Italy
• Jun 2023 'Efficacy and safety of JAK inhibitors' Milan Italy
• Jun 2023 'Aromatase inhibitors and fracture prevention' podcast for VuMedi USA
• Jun 2023 'EULAR 2023 highlights' podcast for VuMedi USA
• Jun 2023 'Key Insights from EULAR 2023: An Interdisciplinary Expert Roundtable Discussion' webinar for European Medical Journal
• Jun 2023 'Upadacitinib in real world - case stories' Midlands rheumatology meeting Birmingham UK
• Jun 2023 'JAK1 inhibition - efficacy and safety' East Sussex rheumatology forum UK
• Jul 2023 'Real world inights into RA and PsA management' national webinar London UK
• Jul 2023 'Romosozumab in osteoporosis' National osteoporosis meeting London UK
• Jul 2023 'JAK1 inhibitor and RA' Rheumatology nurse meeting Doncaster UK
• Jul 2023 'Highlights of BSR and EULAR 2023' regional rheumatology nurse forum Newmarket UK
• Jul 2023 'Real world data of IL17 inhibition' Wales rheumatology forum Cardiff UK
• Sep 2023 'Role of anti IL17 therapy in pain management' SouthWest Rheumatology forum Somerset UK
• Sep 2023 'Anabolic therapy in osteoporosis' National Osteoporosis meeting London UK
• Sep 2023 'Primary investigators - dine and learn event' Bedfordshire researchers forum Luton UK
• Oct 2023 'JAK inhibitors - clinical case management' Isle of Wight UK
• Nov 2023 'CPPD - its many faces' East of England Rheumatology registrars training day Newmarket UK
• Nov 2023 'Learnings from research trip to Netherlands' Grand round Luton UK
• Nov 2023 'Abnormal LFTs in Spondyloarthritis' National nurse forum Leeds UK
• Nov 2023 'How to evaluate a patient with psoriatic disease' National nurse forum Leeds UK
• Nov 2023 'Psoriatic nail disease' National nurse forum Leeds UK
• Nov 2023 'Aromatase inhibitors and osteoporosis - new guidelines implementation audit' Clinical audit & effectiveness committee meeting Luton UK
• Nov 2023 'Real world experience of SpA management' National webinar London UK
• Nov 2023 'Learnings from ACR convergence' Luton UK
• Nov 2023 'ACR highlights' European Medical Journal global webinar London UK
• Nov 2023 'Management of Psoriatic disease' Dermatologists forum Peterborough UK
• Dec 2023 'Complex clinical cases' East of England StR training day Newmarket UK

2022

• Jan 2022 ‘How to keep joints healthy’ International seminar at Punjab University Lahore Pakistan
• Jan 2022 ‘Management of psoriatic arthritis with JAK inhibitors’ Tameside Greater Manchester MDT
• Jan 2022 ‘All you need to know about inflammatory arthritis’ Two-day workshop Cheshire UK
• Jan 2022 ‘Axial psoriatic arthritis management’ Lancaster Rheumatology meeting UK
• Feb 2022 ‘Management of early inflammatory arthritis’ East of England GP forum Luton UK
• Feb 2022 ‘Role of guselkumab in the management of psoriatic arthris’ National webinar UK
• Feb 2022 ‘Spondyloarthritis overlap’ Home counties GP education session Bedford UK
• Feb 2022 ‘Role of JAK inhibitors in RA’ East of England nurse forum Hitchin UK
• Mar 2022 ‘Ultrasound for registrars’ East of England registrars meeting Cambridge UK
• Mar 2022 ‘How to write a business case’ East of England registrars meeting Newmarket UK
• Mar 2022 ‘Role of anti IL-17 therapy in psoriatic arthritis’ Northwest Rheumatology meeting Newcastle UK
• Mar 2022 ‘Psoriatic arthritis management – here and now’ National nurse meeting Birmingham UK
• Mar 2022 ‘Aromatase inhibitors and skeletal health – do new guidelines prevent fractures?’ International Osteoporosis Foundation international online meeting
• Mar 2022 ‘Aromatase inhibitors and skeletal health – natural history and interventional epidemiology’ International Osteoporosis Foundation international online meeting
• Apr 2022 ‘Role of Upadacitinib in inflammatory arthritis’ Rheumatology MDT meeting Oxford UK
• Apr 2022 ‘Baricitinib in RA’ East Kent Rheumatology meeting Canterbury UK
• Apr 2022 ‘Drive-through phlebotomy – is this the future?’ British Society of Rheumatology poster presentation Glasgow UK
• May 2022 ‘SELECTing the right patient for JAK inhibitor’ South East Rheumatology meeting Isle of Wight UK
• May 2022 ‘Role of MRI in choosing right AxSpA patient’ West Midlands Rheumatology meeting Coventry UK
• May 2022 ‘JAK inhibitors – latest data’ King’s College London UK
• May 2022 ‘Learnings from BSR’ East of England Nurse network meeting Newmarket UK
• May 2022 ‘Role of IL17 inhibition in psoriatic arthritis’ Scotland MDT forum Glasgow UK
• May 2022 ‘JAK inhibitors – efficacy and safety’ MDT meeting Ipswich UK
• May 2022 ‘Clinical cases of Upadacitinib’ national rheumatology webinar Stevenage UK
• May 2022 ‘R&D success in Bedfordshire hospitals’ Leadership engagement forum Bedford UK
• Jun 2022 ‘Aromatase inhibitors and fracture prevention – do new guidelines work in real world?’ EULAR oral presentation Copenhagen Denmark
• Jun 2022 ‘Taking history from a complex RA patient’ Three counties rheumatology nurse meeting Luton UK
• Jun 2022 ‘Baricitinib in RA – real world experience’ Midlands rheumatology meeting Northampton UK
• Jun 2022 ‘How to evaluate inflammatory arthritis’ GP meeting Harpenden UK
• Jun 2022 ‘Role of JAK inhibitors in inflammatory arthritis’ South East rheumatology meeting Portsmouth UK
• Jul 2022 ‘Why do doctors ask the questions they ask?’ National rheumatology meeting Chesham UK
• Jul 2022 ‘Upadacitinib in seronegative arthritis’ Nurse meeting Stratford UK
• Jul 2022 ‘Xeljanz and ORAL Surveillance study’ East of England nurse meeting Luton UK
• Aug 2022 ‘Rheumatology cases for physios’ Virgin MSK service Luton
• Aug 2022 ‘How to improve access to modern therapies in PsA’ National advisory board Royal Society of Medicine London UK
• Sep 2022 ‘SpA management– real world experience’ national webinar London UK
• Sep 2022 ‘Research – recipe for success’ CRN Eastern MSK speciality group Cambridge UK
• Sep 2022 ‘Anti IL17 role in PsA’ East Midlands Rheumatology meeting Leicester UK
• Sep 2022 ‘Difficult case selection for JAK inhibitors’ national rheumatology nurse forum Birmingham UK
• Oct 2022 ‘Real world experience with Filgotinib’ Essex Rheumatology forum Colchester UK
• Oct 2022 ‘Complex cases treated with JAK1 inhibitors’ All Wales Rheumatology meeting Cardiff UK
• Nov 2022 ‘How to differentiate RA from other arthritides’ East of England nurse network meeting Newmarket UK
• Nov 2022 ‘Osteoporosis for GPs’ Primary care network meeting St Albans UK
• Dec 2022 ‘How to interpret bone parameters in complex osteoporosis patients’ Nurse forum meeting Luton UK
• Dec 2022 ‘Challenging cases and JAKinibs selection’ Biologics coordinators South East pharmacists forum London UK
• Dec 2022 ‘Real world evidence of JAK1 inhibition’ East of England Rheumatology meeting Norwich UK
• Dec 2022 ‘How to improve research recruitment’ Bedfordshire research practitioners forum Flitwick UK
• Dec 2022 ‘Implementing learnings from ACR’ national advisory board meeting London UK

2021

• Feb 2021 ‘Early arthritis service’ national podcast
• Mar 2021 ‘Role of GPs in early arthritis management’ GPST forum Bedfordshire
• Mar 2021 ‘Challenges facing rheumatologists during pandemic’ national meeting RCGP London
• Apr 2021 ‘Role of Baricitinib in atopic dermatitis’ chair regional meeting East of England
• Apr 2021 ‘New agents in atopic dermatitis’ chair regional meeting North East England
• Apr 2021 ‘Fracture prevention in primary care’ GP federation meeting Buckinghamshire
• Apr 2021 ‘Management of osteoporosis in hyperoxaluria’ regional nephrology meeting Hertfordshire
• May 2021 ‘Service mapping and allied health professionals’ West Anglia NHS organisation
• Jun 2021 ‘Should everyone trial SC methotrexate prior to advanced therapy’ EULAR invited poster round
• Jun 2021 ‘Management of complex rheumatoid arthritis’ national webinar
• Jul 2021 ‘Inflammatory arthritis for GPs’ GPST forum Bedfordshire
• Jul 2021 ‘Role of JAK inhibitor in rheumatoid arthritis’ All Wales rheumatology meeting Cardiff
• Jul 2021 ‘National advisory board presentation for the launch of anti IL23 strategy’ Royal College of Physicians London
• Aug 2021 ‘Changing landscape in rheumatoid arthritis’ regional meeting Bedfordshire
• Sep 2021 ‘Management of moderate rheumatoid arthritis’ regional meeting Bedfordshire
• Sep 2021 ‘Challenging case of psoriatic arthritis and rebound psoriasis with TNF inhibitors' National nurse meeting Birmingham
• Sep 2021 ‘Multifaceted crystal arthritis’ East of England training forum
• Sep 2021 ‘Role of JAK inhibitors in pain’ chaired national meeting satellite forum Luton
• Oct 2021 ‘Advanced therapies for rheumatology nurse specialists’ East of England Nurse training forum Newmarket
• Oct 2021 ‘Role of anti IL6 therapy in rheumatoid arthritis’ British Soceity of Rheumatology national case based conference
• Oct 2021 ‘Impact of NICE guidance on moderate rheumatoid arthritis’ chaired national road show’s satellite forum East of England
• Nov 2021 ‘Role of anti IL17 therapy in axial psoriatic arthritis’ North East rheumatology forum
• Nov 2021 ‘Extra-articular manifestations of rheumatic diseases’ International rheumatology conference Hong Kong and China
• Nov 2021 ‘Management of atopic dermatitis and role of baricitinib’ chaired Midlands dermatology meeting
• Dec 2021 ‘Ixekizumab in psoriatic arthritis and psoriasis’ chaired South West dermatology forum
• Dec 2021 ‘cDMARDs uptake and intolerance in rheumatic diseases’ regional meeting Bedfordshire
• Dec 2021 ‘Role of metabolic bone nurse specialist’ regional nurse meeting Bedfordshire
• Dec 2021 ‘Crystal arthritis –its many faces’ Indian rheumatology society national conference
• Dec 2021 ‘Psoriatic arthritis and its domains’ Scottish regional meeting
• Dec 2021 ‘JAK inhibitors – real world experience’ national podcast

2020

• Jan 2020 ‘Nurse led osteoporosis service’ Audit meeting Luton
• Jan 2020 ‘How to recognise inflammatory arthritis’ Patient forum Spire Harpenden
• Jan 2020 ‘How to differentiate inflammatory and mechanical pain’ Pain form Luton
• Jan 2020 ‘How to get involved in clinical research’ Grand round Luton
• Mar 2020 ‘An unusual headache’ East Anglia Rheumatology forum Newmarket
• Mar 2020 ‘An overview of COVID trials’ Trust forum Luton
• Apr 2020 ‘RECOVERY trial – recruitment and training’ Online forum Luton
• Apr 2020 ‘An unusual HLH like COVID19 presentation in a young adult’ HLH across specialities collaboration national meeting
• May 2020 ‘COVID trials and patient benefits’ Workforce update Luton
• Jul 2020 ‘Learnings from COVID global registries’ National webinar
• Jul 2020 ‘Clinical application of JAK-1 inhibition in RA’ National advisory meeting London (online)
• Jul 2020 ‘Management of acute monoarthritis’ GP online forum Luton
• Aug 2020 ‘Early arthritis and primary care’ GP online forum Luton
• Aug 2020 ‘Learnings from virtual clinics’ National webinar
• Sep 2020 ‘Reach beyond the standard of care’ Rheumatology East Midlands forum (online webinar)
• Sep 2020 ‘Polyarthritis and role of GPs’ GP online forum Spire
• Oct 2020 ‘Alternative therapies for an unusual headache’ Grand round Bedfordshire
• Oct 2020 ‘Inflammatory back pain for primary care’ GP forum Harpenden
• Nov 2020 ‘Disease of Emperors’ GP forum Spire
• Nov 2020 ‘Role of annual review and remote medicine in Rheumatology service’ National meeting London (online)
• Nov 2020 ‘COVID update’ Bedfordshire Trust
• Dec 2020 ‘Psoriatic arthritis – its many facets’ GP forum Bedfordshire

2019

• Jan 2019 ‘CPPD – what GPs need to know’ regional GP meeting Luton
• Feb 2019 ‘Inflammatory arthritis’ Herts GP group St Albans
• Feb 2019 ‘Acute monoarthritis and the role of GPs’ Bucks/Herts GP network meeting
• Mar 2019 ‘Osteoporosis – an impending disaster’ Beds/Herts GP group Redbourn
• Mar 2019 ‘ACPA and RA’ Berkshire meeting Oxford
• Mar 2019 ‘Assessor for GMC’ GMC Manchester
• Apr 2019 ‘Rapidly progressive RA and ACPA’ National rheumatology forum Birmingham
• Apr 2019 ‘GIM assessment for FTP’ GMC Manchester
• Apr 2019 ‘Oligoarthritis and Psoriatic disease’ National forum Birmingham
• Apr 2019 ‘RA and GPs’ GP meeting Herts GP group Stevenage
• Apr 2019 ‘Early inflammatory arthritis’ GP group Luton
• Apr 2019 ‘Chest xray interpretation for nurses’ EoE regional nurse network meeting Newmarket
• May 2019 ‘Osteoporosis and RA’ National osteoporosis meeting Liverpool
• May 2019 ‘How to write a business case’ Regional new consultants meeting Newmarket
• May 2019 ‘How to identify early arthritis’ GP forum Luton
• May 2019 ‘Assessment for doctors in difficulty’ GMC Manchester
• May 2019 ‘Osteoporosis and rheumatic diseases’ National osteoporosis meeting London
• May 2019 ‘ACPA and comorbidities’ East Midlands forum Wolverhampton
• Jun 2019 ‘Antibodies and comorbidities in RA’ North West forum Blackburn
• Jun 2019 ‘Fracture prevention in primary care’ GP forum Radlett
• Jun 2019 ‘Ultrasound in RA’ North London forum London
• Jul 2019 ‘Challenging cases and choice of advanced therapy’ Regional StR training day Newmarket
• Jul 2019 ‘How to improve recruitment to trials’ Research nurses forum Luton
• Jul 2019 ‘Inflammatory arthritis – critical role of GPs’ East Anglia GP forum Hatfield
• Jul 2019 ‘Vertebral fracture management’ GP teaching St Albans
• Aug 2019 ‘What is arthritis’ patient and public forum Hemel Hempstead
• Aug 2019 ‘Ultrasound of small joints’ regional training day London
• Aug 2019 ‘How to identify osteoporosis in community’ GP education session Edelsborough
• Sep 2019 ‘Immunlogy for nurses’ EoE nurse network meeting Norwich
• Sep 2019 ‘Place of IL-17 inhibition in the management of Spondyloarthropathy’ National meeting Leeds
• Sep 2019 ‘Place of Jak inhibitors in the management of RA’ EoE nurse network meeting Norwich
• Sep 2019 ‘Assessment of osteoporosis’ National osteoporosis health professionals meeting Luton
• Sep 2019 ‘Osteoporosis case management’ National osteoporosis health professionals meeting Luton
• Sep 2019 ‘DMARD monitoring for GPs’ Luton
• Oct 2019 ‘Vertebral fracture prevention’ Beds GP meeting Edelsborough
• Oct 2019 ‘How to manage comorbidities in RA’ National webinar London
• Oct 2019 ‘How to recognise SpA in primary care’ Luton GPs meeting
• Oct 2019 ‘Role of anti IL17 in the management of PsA’ Essex rheumatology meeting Chelmsford
• Oct 2019 ‘ACPA and its role in comorbidities’ International webinar London
• Oct 2019 ‘Challenging RA patient – what does it look like’ National steering committee London
• Oct 2019 ‘Radiology for nurses’ Somerset nurses forum Bath
• Oct 2019 ‘Early inflammatory arthritis’ Bedfordshire GP meeting Luton
• Oct 2019 ‘How to identify rapidly progressive RA patient’ Somerset nurses forum Bath
• Nov 2019 ‘Elusive soft tissue disorders’ Regional specialty forum Newmarket
• Nov 2019 ‘Intricacies of crystal arthritis’ Spire Harpenden GP forum
• Nov 2019 ‘How to set up an award winning early arthritis clinic’ Bristol Rheumatology forum
• Dec 2019 ‘Different faces of spondyloarthropathy’ GP meeting Stevenage
• Dec 2019 ‘Complex RA – how to recognise and treat’ National special interest steering committee London

2018

• Jan 2018 ‘Role of synacthen in the management of gout’ Syon Park London
• Jan 2018 ‘Early arthritis service is cost effective’ BSR & NICE visit Luton
• Mar 2018 ‘Rheumatology for maternal medicine’ RCOG StR meeting Luton
• Mar 2018 ‘Role of secukinumab in SpA’ London
• Mar 2018 ‘Challenging case of gout’ Rheumatology meeting Lincoln
• Apr 2018 ‘Role of Canakinumab in post MI management – what can rheumatologist add’ Royal College of GPs London
• Apr 2018 ‘PEST screening in primary care’ Luton GPs meeting
• May 2018 ‘DMARD monitoring and the role of nurse specialists’ Newmarket at East of England CNS regional forum
• May 2018 ‘Vero trial and it’s clinical implications’ Lilly meeting London
• May 2018 ‘Management of gout and role of Synacthen’ Cardiff at Wales Rheumatology forum
• Jun 2018 ‘How to triage inflammatory back pain’ Luton Extended scope therapists triage service
• Jun 2018 ‘Role of ACPA in the management of RA’ ACPA academy London
• Jun 2018 ‘Rheumatology’s role in MDT service’ Watford Combined rheum/derm/gastro meeting
• Jun 2018 ‘Case studies in osteoporosis and new therapies’ Newmarket at East of England StR forum
• Jun 2018 ‘Inflammatory back pain vs EDS related back pain’ Luton GP meeting
• Jul 2018 ‘Launch of biosimilars in the UK’ Frankfurt Germany at Biosimilars academy
• Jul 2018 ‘Choice of biologics in ankylosing spondylitis’ Worcester Rheumatology meeting
• Jul 2018 ‘CPPD – its many faces’ Newmarket East of England StR forum
• Jul 2018 ‘Role of ACPA in the management of RA’ Southend Rheumatology meeting
• Sep 2018 ‘Management of vertebral fractures’ Kettering Rheumatology meeting
• Sep 2018 ‘Role of depo tetracosactide in crystal arthritis’ Southend Grand round
• Oct 2018 ‘Doppler Ultrasound in inflammatory arthritis’ Leeds Rheumatology meeting
• Nov 2018 ‘How to treat inflammatory arthritis in primary care’ GP network meeting Luton
• Nov 2018 ‘The long road to JAK inhibition’ Regional network meeting London
• Nov 2018 ‘Crystals – old is new’ Acute & General Medicine conference EXCEL London
• Nov 2018 ‘Psoriatic arthritis case management’ National nurse meeting London
• Nov 2018 ‘Interpretation of X-rays for clinical practice – what Rheumatology nurses need to know’ Regional nurse meeting Newmarket
• Dec 2018 ‘OSCE assessment for GMC FTP panel’ GMC Manchester

2017

• Jan 2017 ‘Place of Adaliumumab in RA management’ London RCGP meeting
• Jan 2017 ‘Online educational tools in rheumatology’ London Rheumatology meeting
• Jan 2017 ‘Role of synacthen in the treatment of gout’ London Rheumatology forum
• Mar 2017 ‘Choosing the right biologic agent’ Exeter Learning Rheum Nurse specialist forum
• Mar 2017 ‘Role of IL17 inhibitor in the management of SpA’ London Rheumatology meeting
• Apr 2017 ‘Choosing the right biologic agent’ Exeter Learning Rheum Nurse specialist forum
• May 2017 ‘Back pain’ Regional CMT teaching Luton
• Jun 2017 ‘How to choose right biologic in PsA’ EULAR symposium Madrid Spain
• Jun 2017 ‘Training Rheumatology nurse specialists – what does the future hold?’ EULAR Madrid Spain
• Jun 2017 ‘Biologics in AS’ Cambridge Rheumatology meeting
• Jul 2017 ‘Changing landscape in RA therapeutics’ Royal College of GPs London
• Sep 2017 ‘Modern management of gout’ International webinar London
• Sep 2017 ‘Role of Certolizumab in PsA & AS’ London
• Sep 2017 ‘Challenging cases in RA’ Mission Remission meeting London
• Oct 2017 ‘Place of Tocilizumab in the management of RA’ Lister Rheumatology meeting Stevenage
• Oct 2017 ‘Role of ultrasound in synovitis and practical demonstration’ Lister Rheumatology meeting Stevenage
• Oct 2017 ‘Biosimilars – here and now’ Biosimilar academy Merton College Oxford
• Nov 2017 ‘Assessing for GMC’ GMC Manchester
• Nov 2017 ‘Treating gout – crystallising the evidence’ Acute Medicine Conference EXCEL London
• Nov 2017 ‘Management of rapidly progressive RA’ King’s Fund London
• Nov 2017 ‘Management of gout in the elderly’ Geriatric meeting

2016

• Apr 2016 ‘Management of RA – clinical research to clinical practice’ Basildon Essex Rheumatology Society meeting
• Apr 2016 ‘Management of osteoporosis’ Luton Endocrinology Speciality Registrar meeting
• Jun 2016 ‘Management of a rapidly progressive RA patient’ Southend Rheumatology meeting
• Jul 2016 ‘CPPD – its many faces’ Northampton Rheumatology Speciality Registrar meeting
• Aug 2016 ‘Rituximab in the management of RA’ Ipswich Rheumatology meeting
• Sep 2016 ‘Biosimilars in Rheumatology’ London Learning Rheum National Rheumatology nurse specialists meeting
• Sep 2016 ‘Optimising biologic treatment’ London Learning Rheum National Rheumatology nurse specialists meeting
• Sep 2016 ‘Management of gout’ Luton General Practitioners’ meeting
• Oct 2016 ‘Education in Rheumatology’ London Rheumatology board
• Nov 2016 ‘Challenging RA cases’ London Rheumatology meeting
• Dec 2016 ‘Optimising gout management and difficult cases’ Luton GP meeting